ß-L-1-[5-(E-2-bromovinyl)-2-(hydroxymethyl)-1,3-(dioxolan-4-yl)] uracil (L-BHDU) inhibits varicella zoster virus (VZV) replication in cultured cells, human skin, and in SCID-Hu mice with skin xenografts. VZV thymidine kinase converts L-BHDU to monophosphate (MP) and diphosphate (DP) forms, but the triphosphate form was not detected in infected cells and the antiviral mechanism was unknown. Given its similar structure to uridine, we asked if L-BHDU interfered with viral DNA replication via inhibition of the purine and/or pyrimidine biosynthesis pathways. Addition of purines to the medium was unable to restore VZV replication in the presence of L-BHDU. In contrast, excess thymidine and uridine in proportion to L-BHDU restored VZV replication, suggesting that the active form of L-BHDU interfered with pyrimidine biosynthesis. However, addition of thymidine and uridine failed to restore VZV replication in nondividing cells treated with L-BHDU. Like other herpesviruses, VZV infection increased thymidine triphosphate (dTTP) in confluent cells while L-BHDU treatment decreased the dTTP pool by nearly 4-fold. The active form(s) of L-BHDU did not interfere with cellular metabolism, suggesting viral target(s).
5 µM when infused into the instrument. LC-MS analysis was performed using a microspray triple quadrupole system. Samples were separated on a porous graphite column (Hypercarb 100x 2.1 mm column, ThermoScientific) using a Dionex Ultimate 3000 HPLC coupled to a Quantum Access Max mass spectrometer (Thermo Scientific) and run in the SRM negative scan mode.
The solvent system was 2 mM ammonium acetate (pH 10, Solution A) and 100% acetonitrile (Solution B) in a 6.5 minute HPLC method. Using a flow rate of 400 µL/min, the column was equilibrated at 40°C in 2% Solution B for 1 min, ramped to 25% Solution B in 2.5 min, ramped to 70% Solution B in 1 min, and then held there for 1 min before being returned to the equilibration condition of 2% Solution B for the remainder (2 min) of the run. Analysis of the extracted ion chromatograms and peaks was performed with the Thermo Scientific LC Quan and XCalibur software. 5 point smoothing using the Boxcar method and integration using Thermo Scientific's "ICIS" algorithm were employed.
Statistical analysis
GraphPad Prism 5.02 for Windows (Graph-Pad Software, San Diego, CA, www.graphpad.com) was used for statistical calculations. A p ≤ 0.05 was considered statistically significant.
Results

Pyrimidines rescued VZV from L-BHDU in primary cells
Nucleoside analogues often affect nucleotide metabolism (Galmarini et al., 2001; Parker, 2009) , and so we hypothesized that the active form of L-BHDU might prevent VZV replication by this mechanism. To address this question, VZV cultures in two different cell types were treated with L-BHDU and various purine and pyrimidine bases were added in excess to determine whether they could rescue virus replication ( Fig.1.A ). If a purine or pyrimidine rescues virus replication, then that pathway is likely blocked by the active form of the drug. In this assay, the amount of purine or pyrimidine was held constant while the drug concentration was serially decreased 2-fold. Purines did not rescue viral replication in the presence of L-BHDU. Conversely, addition of the pyrimidines thymidine and uridine rescued VZV replication and reversed the inhibitory effect of L-BHDU in a dose dependent manner. A 200:1 ratio of thymidine to L-BHDU restored VZV replication while uridine required 800:1 for the same effect. This was observed in HFFs, primary dermal fibroblasts, (Fig.1 .A) but not in MeWos, a melanoma cell line ( Fig.1.B ). Dihydroorotate (DHO) and orotate (intermediates in the pyrimidine de novo synthesis pathway) did not rescue VZV replication. This suggested that L-BHDU blocked the pyrimidine salvage pathway in VZVinfected cells.
Cell proliferation enzymes and VZV ORF13 (thymidylate synthase) were required for pyrimidines to rescue VZV from L-BHDU
The abundance of nucleotides in a cell, known as the nucleotide pool, varies greatly during the cell cycle. Nucleotides are scarce in confluent or quiescent cells whereas dividing cells require high concentrations of dNTPs for genome synthesis during S phase (Hollenbaugh et al., 2013) .
Herpesviruses use dNTPs for viral DNA replication, thus they encode metabolic enzymes involved in nucleotide metabolism (Vastag et al., 2011) . It was not known whether the antiviral effects of L-BHDU could be overcome by exogenous pyrimidines in confluent cells, in which the enzymes required for dTTP synthesis are not expressed. VZV grew normally in confluent HFFs and was inhibited in the presence of L-BHDU (Fig. 2.B and D). This antiviral effect was not rescued by the addition of excess thymidine or uridine, in contrast to the results in dividing cells. VZV is one of two human herpesviruses other than HHV8 that encodes a viral thymidylate synthase (TS) (Gáspár et al., 2002) , thus cellular TS may not be required in confluent cells.
Indeed, the TS gene encoded by ORF13 is not essential and a stop codon mutant, VZV13S, grows normally (Cohen and Seidel, 1993) . TS is essential for regulating the balanced supply of dNTP precursors for DNA replication (Kaneda et al., 1990) . Therefore, the intracellular availability of dUMP may be the rate-limiting step in dTMP biosynthesis and hence critical for efficient viral replication in quiescent cells (Gribaudo et al., 2003) . We tested whether addition of thymidine or uridine could rescue VZV 13S replication from L-BHDU inhibition in dividing and non-dividing cells. As expected, VZV 13S grew well in both dividing and non-dividing cells in the absence of L-BHDU. In non-dividing cells neither thymidine nor uridine restored VZV 13S replication ( Fig. 2.D) . Interestingly, thymidine but not uridine restored VZV 13S replication in dividing cells ( Fig. 2 .C). Thus, viral TS was important for utilizing uridine to overcome the effects of L-BHDU. Furthermore, cellular enzymes in proliferating cells were also necessary to rescue WT and 13S VZV from L-BHDU.
Active L-BHDU did not inhibit cell proliferation
To determine whether the active form of L-BHDU affected cellular metabolism, a proliferation assay was performed. L-BHDU is phosphorylated to its active form by viral thymidine kinase (TK) and not by cellular TK, thus we used a recombinant HFF-TK cell line stably expressing VZV TK to produce L-BHDU-MP and -DP. BVdU was a positive control because its monophosphorylated form is cytostatic in cells expressing viral TK. BVdU-MP inhibits cellular thymidylate synthase and subsequently cellular proliferation (Balzarini et al., 1994 (Balzarini et al., , 1985 . HFF-TK cells grew normally in medium and with vehicle ( Fig.3 ). As expected, serum starvation and BVdU treatment significantly inhibited cell proliferation after 72 h. Addition of thymidine but not uridine restored proliferation in the cells treated with BVdU ( Fig.3) , which reflects the known blockade of the de novo biosynthesis pathway by BVdU-MP inhibition of cellular TS.
Conversely, HFF-TK cells grew normally in the presence of L-BHDU at the EC90 concentration, suggesting that L-BHDU-MP and/or -DP did not inhibit cellular nucleotide metabolism.
L-BHDU suppressed the increase in dTTP in VZV-infected cells
One response to herpesvirus infection is a marked increase in the level of dTTP in the cell, which is consistent with the need to replicate viral DNA (Daikoku et al., 1991; Vastag et al., 2011) . We hypothesized that L-BHDU indirectly inhibits VZV replication by decreasing the cellular dTTP pool, which prevents viral DNA synthesis. The relative amounts of various nucleotides were measured by HPLC-MS/MS in dividing or confluent cells that were infected with VZV and treated with L-BHDU. ARPE-19 retinal pigment epithelial cells were used for this experiment because they are highly permissive for VZV infection even when contact-inhibited, and they have more abundant dNTPs than HFFs (Sloutskin et al., 2013) . As expected, nucleotides increased in ARPE-19 cells when they were released from contact inhibition for 1 day (Fig.4 , Table 1 ). When confluent ARPE-19 cells were infected with VZV for 1 day, all the nucleotides increased to varying degrees. The level of dTMP was 4-fold higher than dividing ARPE-19 cells while dTDP and dTTP were similar. The levels of dUMP, dUTP, and dCTP were less than dividing ARPE-19 cells but more than confluent cells. At this point duplicate cultures of VZV-infected ARPE-19 cells were either treated with L-BHDU or the medium was refreshed.
In untreated, VZV-infected ARPE-19 cells, the levels of dTDP and dTTP continued to increase while L-BHDU treatment prevented this. The level of dTMP remained high in VZV-infected cells treated with L-BHDU. Thus L-BHDU prevents the accumulation of dTTP in VZV-infected cells and thereby blocks viral DNA replication.
Discussion
This study demonstrates that L-BHDU inhibits VZV replication by decreasing the cellular dTTP pool by interfering with the pyrimidine biosynthesis pathway (Fig. 5 ). There are two routes to the synthesis of pyrimidines; the de novo and salvage pathways. Some compounds targeting the de novo pyrimidine biosynthesis pathway have antiviral properties (Fischer et al., 2013; Hoffmann et al., 2011; Wang et al., 2011) . Our results point away from the de novo pathway because addition of intermediates such as orotate and DHO failed to restore VZV replication in the presence of L-BHDU. On the other hand, pyrimidine salvage pathway substrates thymidine and uridine rescued VZV replication from L-BHDU inhibition. The activity of the pyrimidine de novo and salvage pathways varies with the developmental stage of the cell. The de novo pathway is low in fully differentiated cells, whereas it is indispensable in proliferating cells (Evans and Guy, 2004) . Rapidly dividing cancer cells have much higher levels of cellular dNTPs than primary cells (Amie et al., 2013) and this can reduce phosphorylation of antiviral nucleoside analogues (Karlsson et al., 1986) . This may explain why L-BHDU was more effective in primary HFF than in MeWo cells (melanoma cell line), and why addition of thymidine and uridine did little to rescue VZV replication in MeWo cells. Addition of thymidine or uridine did not restore VZV replication in confluent HFFs. In non-dividing cells where cellular enzymes are lacking, dNTPs were insufficient for virus replication to resume (Cheng and Traut, 1987; Staub and Eriksson, 2006) .
Though herpesviruses rely primarily on the metabolic capabilities of their cellular hosts for replication, all herpesviruses encode enzymes that are involved in nucleotide metabolism (Vastag et al., 2011) . VZV encodes several enzymes that play critical roles in viral replication, especially those involved in the pyrimidine biosynthesis pathway (Reviewed in Cohen, 2010 , 1996 . Herpesviruses also actively redirect host cell metabolism to increase the dNTP pool, especially dTTP, by inducing cellular enzymes (Gribaudo et al., 2003 (Gribaudo et al., , 2002 Vastag et al., 2011) . We found that VZV infection of non-dividing cells increased the cellular dTTP pool along with other dNTPs to facilitate viral replication (Fig. 4) . Due to the expression of viral enzymes involved in pyrimidine biosynthesis pathway including vTS and increased dNTP pools, VZV replicated well in non-dividing cells.
The maintenance of balanced dNTP pools is critical for viral DNA replication and perturbation can lead to inhibition of virus replication. ACV and bucyclovir (BCV) treatment of HSV-1 infection increase cellular dNTP pools including dTTP (Furman et al., 1982; Karlsson et al., 1986; Prichard et al., 1993) . ACV-TP and BCV-TP both target viral DNA polymerase and cause chain termination. This results in reduced utilization of dNTPs and leads to accumulation in treated, infected cells (Furman et al., 1982) . Interestingly, L-BHDU lowered the dTTP pool in (Longley et al., 2003) .
Rescue of VZV replication in the presence of L-BHDU by addition of excess uridine
suggests a major role for TS in supplying dTMP via dUMP to restore the cellular dTTP pool.
Due to structural similarities between dUMP and L-BHDU-MP, it is possible that L-BHDU-MP might compete with dUMP for the active sites on TS, either viral or cellular. Both cellular and viral thymidylate synthases (cTS and vTS) could be targets of active L-BHDU in infected cells.
We found that HFF-TK cells grew normally when active L-BHDU was present, which excludes cTS and other proliferation enzymes as targets. This conclusion was strengthened by our finding that uridine rescued wt VZV in subconfluent HFFs with L-BHDU, but not VZV 13S strain that does not express vTS. This points to the key role of vTS in conversion of dUMP to dTMP to replenish the dTTP pool and suggests that vTS could be a potential target of L-BHDU-MP.
However, we found that uridine could not rescue wt or 13S VZV in confluent HFFs in the presence of L-BHDU. The reason why addition of uridine failed to restore VZV replication in confluent cells is due to low translation and activity of uridine kinase and UMP kinase (Cheng and Traut, 1987; Staub and Eriksson, 2006) . Without these cellular enzymes, uridine fails to convert to dUMP and vTS lacks its substrate for dTMP synthesis. However, synthesis of dTMP was not sufficient to overcome the antiviral effects of active L-BHDU in confluent cells. Thus there are other targets of active L-BHDU that are necessary for VZV replication in quiescent cells. Ribonucleotide reductase (RNR) catalyzes formation of high concentrations of deoxynucleotides for viral DNA synthesis (Spector et al., 1989 (Spector et al., , 1987 . RNR is essential for virus replication in non-dividing cells (Duan et al., 1998; Sienaert et al., 2002) . The natural substrates of RNR are ribonucleoside diphosphates, so it would be interesting to test whether L-BHDU-DP inhibits VZV-encoded RNR. The exact molecular mechanisms that mediate the depletion of dTTP pool by L-BHDU active form(s) have not been fully elucidated and will require further investigation. A complete understanding of the mechanism of action of L-BHDU at the molecular level is an important scientific objective for design and development of more effective antiviral therapy.
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